Temasek To Invest $85Mn In Molbio Diagnostics

Goa-based Molbio Diagnostics has announced that Temasek has invested $85 million in the company. 

Onboarding Temasek, alongside existing investors such as Motilal Oswal Alternates, will further strengthen and accelerate the company’s ability to develop and commercialize a host of near-care technologies based on clinical need gaps.

Furthermore, this will also help the company in fast-tracking its efforts to take the Truenat® platform to global markets, the company said in a statement.

“We are delighted to have Temasek on board. The demand for high-quality, point-of-care molecular diagnostic systems is higher than ever today. The strategic partnership with Temasek will strengthen our ability to provide sustainable choices to address global healthcare challenges,” said Sriram Natarajan, Director and CEO, Molbio Diagnostics.

We see the partnership with Temasek accelerating our efforts to work on newer technologies that address the critical need gaps in diagnosis globally, stated Dr Chandrasekhar Nair, Director and CTO, Molbio Diagnostics.